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Background: Matrix Gla protein (MGP) is known to act as a potent local inhibitor of vascular calcifications.
However, in order to be active, MGP must be phosphorylated and carboxylated, with this last process being
dependent on vitamin K. The present study focused on the inactive form of MGP (dephosphorylated and
uncarboxylated: dp-ucMGP) in a population of hemodialyzed (HD) patients. Results found in subjects being treated
or not with vitamin K antagonist (VKA) were compared and the relationship between dp-ucMGP levels and the
vascular calcification score were assessed.
Methods: One hundred sixty prevalent HD patients were enrolled into this observational cohort study, including
23 who were receiving VKA treatment. The calcification score was determined (using the Kauppila method) and
dp-ucMGP levels were measured using the automated iSYS method.
Results: dp-ucMGP levels were much higher in patients being treated with VKA and little overlap was found with
those not being treated (5604 [3758; 7836] vs. 1939 [1419; 2841] pmol/L, p <0.0001). In multivariate analysis,
treatment with VKA was the most important variable explaining variation in dp-ucMGP levels even when adjusting
for all other significant variables. In the 137 untreated patients, dp-ucMGP levels were significantly (p < 0.05) associated
both in the uni- and multivariate analysis with age, body mass index, plasma levels of albumin, C-reactive protein, and
FGF-23, and the vascular calcification score.
Conclusion: We confirmed that the concentration of dp-ucMGP was higher in HD patients being treated with VKA. We
observed a significant correlation between dp-ucMGP concentration and the calcification score. Our data support the
theoretical role of MGP in the development of vascular calcifications. We confirmed the potential role of the inactive
form of MGP in assessing the vitamin K status of the HD patients.
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Matrix Gla protein (MGP) is an 11 kDa protein secreted by
chondrocytes and vascular smooth muscle cells (VSMCs)
[1]. MGP acts as a potent local inhibitor of vascular calci-
fications by directly inhibiting calcium precipitation and
crystallization [2,3] and/or by antagonizing bone morpho-
genetic protein (BMP2), which itself promotes osteoblastic
differentiation of VSMCs [4]. MGP-deficient mice have
been shown to develop excessive and premature arterial
calcifications, leading to death by rupture of the aorta in
the first two months of life [2]. In order to be fully active,
MGP must first undergo two posttranslational processes:
the phosphorylation of three serine residues (although the
role of this phosphorylation process is still not well under-
stood) and the carboxylation of five glutamate residues
[5,6]. This explains why it is theoretically possible for
several different isoforms of MGP to be measured in the
plasma (a combination of carboxylated, uncarboxylated
and phosphorylated, unphosphorylated MGP). Different
fragments of MGP may, in fact, have different physiological
roles and meanings [7,8]. In this article, we will focus on
the inactive form of MGP (dephosphorylated and uncar-
boxylated: dp-ucMGP). Because γ-glutamyl carboxylation
is highly dependent on availability of vitamin K [9], it is
possible that the measurement of dp-ucMGP would re-
flect vitamin K status [7,10].
In hemodialysis (HD) patients, vascular calcifications are
precocious, frequent and excessive [11-14]. The association
between the level of vascular calcifications and mortality
has been described in HD patients in various studies
[15-17]. There are several in vitro and in vivo data suggest-
ing a direct link between the decreased availability of vita-
min K and vascular calcification, based on the role of this
vitamin in the activation of MGP [9,18]. Various authors
have described a decreased availability of vitamin K (both
K1 and K2) in patients with chronic kidney disease (CKD)
[19-24]. As a result, the level of the inactive form, dp-
ucMGP, has been found to increase in these patients, in
comparison with non-CKD patients [7,10,21,22,25]. In
addition, vitamin K therapy has been shown to significantly
decrease the levels of dp-ucMGP both in the general popu-
lation [8,26] and HD patients [7,10,27]. Conversely, it has
been shown in the general population and in CKD patients
that vitamin K antagonist (VKA) is associated with higher
dp-ucMGP levels [8,23]. If the same higher concentration
is also observed in dialysis patients is not known. These
results suggest that dp-ucMGP could reflect a person’s
vitamin K status at the vascular level [7,10,21,27-29].
Moreover, it is interesting that, in CKD patients, some
authors have found a significant correlation between
dp-ucMGP levels and vascular calcifications [25] but this
finding has not been confirmed by others [7]. This point is
thus still debatable. In this study, we measured dp-ucMGP
levels in a cohort of HD patients and compared the resultsbetween those being treated or not with VKA. We also
assessed the potential relationship between dp-ucMGP
levels and the vascular calcification score.
Methods
Prevalent hemodialysis patients from three independent
centers in Liège and the surrounding areas in Belgium,
were included in this observational cohort study (Centre
Hospitalier Universitaire du Sart Tilman, Centre Hospitalier
Regional de La Citadelle, Centre Hospitalier Bois de
l’Abbaye de Seraing). From the initial sample (n = 212),
we restricted the analysis to patients who were able and
agreed to have their vascular calcification score measured
(n = 165). Vascular calcifications were assessed by lateral
X-ray radiography (the “Kauppila” method) and the score
(between 0 to 24) was established by the same experienced
investigator (LM) [30,31]. Of the 165 patients, MGP was
not measured in 5 patients, due to technical issues. In the
final sample, 23 patients were being treated with VKA
(acenocoumarol, Novartis Pharma) and 137 patients were
not being treated with this therapy. The following clinical
data were considered: age, gender, body mass index (BMI),
dialysis vintage, previous cardiovascular disease, hyperten-
sion, diabetes and smoking habit. Hypertension was de-
fined as having a blood pressure greater than 140/90 mm
Hg and/or being in receipt of treatment for hypertension.
Diabetes status was obtained from electronic medical files
and/or defined according to being in receipt of treatment
for diabetes. Previous cardiovascular disease was defined
as having a history of myocardial infarction, percutan-
eous coronary artery intervention, cardiac surgery, per-
ipheral artery disease or cerebrovascular disease. Data
were extracted from electronic medical files and com-
pleted through interviews with the patients. Patients were
defined as having a smoking habit if they currently
smoked. All data from the electronic files have been then
confirmed by nephrologists taking care of the patients.
The following laboratory data were studied (one-point
measurements): plasma levels of calcium, phosphorus,
albumin, C-reactive protein (CRP) (measured using the
Modular P autoanalyzer, Roche, Mannheim, Germany), in-
tact parathormone (measured using the Elecsys analyzer,
Roche, Mannheim, Germany), 25-OH vitamin D, bone-
specific alkaline phosphatase (measured using the Liaison
analyzer, Diasorin, Stillwater, MN) and C-terminal Fibroblast
Growth Factor (FGF-23) (measured by ELISA, Biovendor,
Czech Republic). dp-ucMGP was quantified by the first
automated method available on the market (supplied
by IDS, Boldon, UK). A precision profile was determined
using 4 plasma samples (264-2703 pmol/L), measured
twice a day for 10 days. CV intra-assays and inter-assays
were thus measured at 2.9-8.9% and 4.1-13.4%, respect-
ively. The IDS kit was found to be linear up to a value of
9724 pmol/L. We also measured dp-ucMGP levels using
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(normal) range was found to be < 572 pmol/L. Concomitant
therapies were available but not included in the final statis-
tical analysis: 63% were treated by low dosage of calcium
(carbonate or acetate), 25% by sevelamer, 5% by lanthanum,
66% by cholecalciferol and 29% by active vitamin D.
Human subjects procedures in the present study were
in accordance with the ethical standards of the Helsinki
Declaration of 1975. All participants provided their writ-
ten informed consent. The study and the approved con-
sent were approved by the Ethics Committee of the
University Hospital, CHU Sart Tilman “Comité d’éthique
Hospitalo-Facultaire Universitaire de Liège, http://www.
chu.ulg.ac.be/jcms/c_11204/comite-d-ethique-hospitalo-
facultaire”. The Ethics committee of the University Hos-
pital has the authority to approve the study for all par-
ticipating sites. The Belgian number of this study is
B707201215885. Immunodiagnostic Systems (IDS) PLC
provided the kits for measuring dp-ucMGP levels but
the company was not involved in the study design, data
analysis, or preparation of the manuscript.
Statistical analysis
Data were expressed as mean ± standard deviation (SD)
when the distribution was normal and as being in theTable 1 Main clinical characteristics and biological data of th
antivitamin K (VKA) therapy status
Total population Non-treated
n 160 137
Age (yr) 74 [63; 80] 74 [64;
Male gender (%) 44 43
Body mass index (kg/m2) 25.4 [22.6; 30.2] 25.4 [22.6
Dialysis vintage (month) 23 [11; 44] 22 [11;
Previous CVD (%) 65 64
Hypertension (%) 87 85
Diabetes (%) 44 43
Smoking habit (%) 21 21
Calcium (mmol/L) 2.15 ± 0.16 2.16 ±
Phosphate (mg/dL) 4.6 [4.0; 6.0] 4.6 [4
Albumin (g/L) 38 [36; 40] 38 [36;
CRP (mg/L) 5 [2; 13] 5 [2; 1
Intact PTH (pg/mL) 263 [126; 434] 251 [129
25-OH vitamin D (ng/mL) 22 [12; 33] 22 [12;
b-ALP (μg/L) 16 [11; 23] 15 [10;
FGF-23 (RU/mL) 2911 [1039; 7413] 2733 [883
Calcification score (maximum score is 24) 10 [5; 15] 10 [5;
dp-ucMGP (pmol/L) 2148 [1542; 3251] 1939 [1419
Note: conversion factor for units: phosphorus in mg/dL to mmol/L, x0.3229. Data ar
and as median and interquartile range [percentile 25; percentile 75] when not. CVD
bone-specific alkaline phosphatase; dp-ucMGP, dephosphorylated and uncarboxylamedian and interquartile range [IQR] if not. As appropri-
ate, the baseline characteristics were compared between
treated and non-treated groups using the Student’s t-test,
the Mann–Whitney U test or the Chi-square test.
Regression analysis was used to study the potential lin-
ear relationship between the vascular calcification score
and dp-ucMGP levels. A multivariate analysis was also
performed with variables that were found to be associ-
ated with dp-ucMGP in the univariate analysis (p = 0.1).
We defined tertiles according to dp-ucMGP concentrations
and compared the vascular calcification score between the
tertiles using the Mann–Whitney and Kruskal-Wallis tests.
All statistical analyses were conducted using the Medcalc
(Mariakerke, Belgium) and SAS 9.3 (SAS Institute Inc.
Cary, NC) software.
Results
The clinical and biological variables of the total popula-
tion of the study (n = 160) are summarized in Table 1.
The concentration of dp-ucMGP was high in our HD
patients: 2148 [1542; 3251] pmol/L. Table 1 also shows
the differences in the clinical and biological variables be-
tween the 23 patients being treated with VKA and the 137
not being treated with VKA. No significant difference was
observed regarding clinical characteristics, except in thee total population of the study and according to
with VKA Treated with VKA P (between treated and non-treated)
23
81] 71 [59; 79] NS
52 NS
; 30.2] 27.3 [24.7; 33.3] NS





0.15 2.14 ± 0.20 NS
; 6] 5.1 [4.3; 5.7] NS
40] 40 [38; 40] NS
3] 4 [3; 9] NS
; 423] 291 [125; 570] NS
33] 19 [13; 25] NS
23] 19 [13; 29] NS
; 7597] 3179 [2391; 6676] NS
15] 11 [6; 17] NS
; 2841] 5604 [3758; 7836] <0.0001
e expressed as mean ± standard deviation (SD) when distribution was normal
, cardiovascular disease; CRP, C-reactive protein; PTH, parathormone; b-ALP
ted; NS, non significant (p > 0.05).
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slightly higher in patients being treated with VKA. We ob-
served a significant difference in dp-ucMGP levels, with a
much higher concentration in patients being treated with
VKA and little overlap with patients not being treated
with VKA (5604 [3758; 7836] vs. 1939 [1419; 2841] pmol/L,
p <0.0001) (Figure 1). In the multivariate analysis (general-
ized linear model) on all patients, treatment with VKA
was, by far, the most important variable explaining vari-
ation in dp-ucMGP levels (R2 = 0.59, p < 0.0001).
In the 137 patients not being treated with VKA, dp-
ucMGP levels were significantly (p < 0.05) associated in
the univariate analysis with age and BMI, and with plasma
levels of albumin, CRP and FGF-23. All these associations
were positive, except with albumin. Also, a slight but sig-
nificant correlation was found between dp-ucMGP levels
and the calcification score (r = 0.17, p = 0.049) (Figure 2).
In the multivariate model, dp-ucMGP levels were signifi-
cantly associated with BMI (p = 0.0032), and with plasma
levels of albumin (p = 0.0368), FGF-23 (p = 0.002) and
CRP (p = 0.0012), as well as with the calcification score
(p = 0.0206) (Table 2).
Considering the tertiles of dp-ucMGP levels (at 1647
and 2404 pmol/L), subjects in the highest tertile (tertile 3)
had a significantly higher vascular calcification score than
those in tertile 1 (but not compared with tertile 2): 9 ± 6
versus 11 ± 6 (p = 0.0414) (Figure 3). Compared to tertile 1,
tertile 3 included more men with a higher BMI and with
lower albumin levels.
Discussion
Our results confirmed that dp-ucMGP concentrations are
higher in dialysis patients with a median concentration ofFigure 1 Median concentration of dp-ucMGP in patients treated with
(n = 137) (5604 [3758; 7836] vs. 1939 [1419; 2841] pmol/L, p <0.0001)2148 [1542; 3251] pmol/L, whereas the normal range was
found to be < 572 pmol/L in 62 healthy subjects. We also
showed for the first time that dialysis patients treated by
VKA have significantly higher dp-ucMGP concentrations
than not treated dialysis patients. Lastly, we showed a mild
but significant correlation between dp-ucMGP and vascu-
lar calcifications. We confirmed that the concentration of
dp-ucMGP was higher in dialysis patients than in the
healthy population we had also tested. Indeed, the median
concentration in our HD population was: 2148 [1544;
3237] pmol/L, which is much higher than concentrations
observed elsewhere in non-CKD and CKD non-HD popu-
lations [7,23,25,26,32]. The mean concentration of dp-
ucMGP in our population (2704 ± 1798 pmol/L) is how-
ever very comparable to the concentration observed by
Schlieper et al. in their 188 HD subjects (2850 ± 1768
pmol/L) [7]. This high concentration of dp-ucMGP in HD
patients is not fully understood. These patients are clearly
sensitive to vitamin K deficiency, and this is likely because
the recommended diet in HD patients is deficient in vita-
min K [19-22,24]. However, decreased excretion or catab-
olism of MGP associated with decreased glomerular
filtration is also a plausible explanation for the molecular
weight of MGP (11 kDa) [7,33]. In addition, a classical ex-
ponential relationship has been observed between dp-
ucMGP and estimated glomerular filtration rate [25].
Lastly, the burden of vascular calcifications in HD patients
could also influence the level of dp-ucMGP (see below)
[25,32].
For the first time in HD patients, we showed here that
VKA treatment strongly and independently impacted,
and actually increased the levels of dp-ucMGP, although
the clinical and biological profiles of these patients wereantivitamin K (VKA) (n = 23) and in patients not treated with VKA
.
Figure 2 Univariate regression between the calcification score and dp-ucMGP (in pmol/L) in patients not treated with VKA (n = 137)
(r2 = 0.02850, p = 0.049).
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apy. Vitamin K is necessary for the carboxylation of
MGP and is thus a key vitamin in the process of MGP
activation [9,18]. An increase in the inactive form of the
protein, dp-ucMGP is thus to be expected. Such an in-
crease in dp-ucMGP levels in VKA treated patients has
already been shown in the general and in CKD popula-
tions but not in HD populations [8,23,25]. In HD patients,
some authors have demonstrated a decrease in dp-ucMGP
levels associated with vitamin K therapy [7,10,27]. Our re-
sults confirm that patients being treated with VKA must
be considered separately in studies involving MGP and
underline the potential role of dp-ucMGP in monitoring
the vitamin K status of HD patients [34].
Because MGP is a potent inhibitor of vascular calcifica-
tions [1,2,4], some authors have suggested that the protein
may be useful in the monitoring or even the detection of
vascular calcifications in CKD or HD subjects [25,35]. In
the present study, we confirmed a significant correlation
between dp-ucMGP levels and the calcification score inTable 2 Variables associated with dp-ucMGP
concentrations in the multivariate model
r p




Calcification score 0.19 0.0206
Note: r is the zero order correlation coefficient for the variable in the
univariate analysis. p is the p value of the variable in the multivariate analysis.
CRP, C-reactive protein; FGF, Fibroblast Growth Factor.the univariate analysis and this association was confirmed
in the multivariate model. Similarly, we found that the pa-
tients in the highest tertile of dp-ucMGP levels had a sig-
nificantly higher calcification score than the patients in
the lowest tertile. Our results confirm those published by
Schurgers et al., who also showed a positive association
(both in univariate and multivariate analysis) between dp-
ucMGP levels and the calcification score in 107 CKD pa-
tients (including 40 HD patients) [25]. Schlieper et al,
however, did not confirm any relationship between dp-
ucMGP levels and the calcification score in 188 HD pa-
tients [7]. Interestingly, these two authors used an ELISA
method to measure dp-ucMGP, which could explain, at
least in part, some discrepancies between their studies
[7,8,25]. For the first time, we used an automated assay
with a high analytical performance. Another potential ex-
planation of discrepant results could be the differences in
techniques applied for calcification detection. Schurgers
and colleagues used the most sensitive technique, i.e. mul-
tislice spiral computed tomography [25], Schlieper used a
modified Adragao score [15], which is an extension of the
Kauppila method [7] and we used the classical Kauppila
method, as recommended by the KDIGO guidelines [30].
In our prevalent HD population, the correlation between
dp-ucMGP levels and the calcification score remained
relatively poor. Also, the overlap between the MGP tertiles
regarding the calcification score was high, making the
measurement of dp-ucMGP levels uncertain, at the indi-
vidual level, in detecting or estimating the burden of the
calcification score. This positive correlation between dp-
ucMGP levels and the calcification score supports how-
ever the theoretical role of MGP in the development of
Figure 3 Comparison of the calcification score in the highest versus the lowest tertile of dp-ucMGP (in pmol/L) (9 ± 6 versus 11 ± 6,
p = 0.0414) in patients not treated with VKA (n = 137).
Delanaye et al. BMC Nephrology 2014, 15:145 Page 6 of 8
http://www.biomedcentral.com/1471-2369/15/145vascular calcifications. It also advocates the need for add-
itional studies, particularly with other active isoforms of
MGP [7,22,32,35-39]. For instance, total uncarboxylated
MGP (which may be partially bioactive) has been negatively
associated with coronary calcification in dialysis patients
[36]. Moreover, reduced levels of non-phosphorylated car-
boxylated MGP (also partially bioactive form of MGP) has
been associated with increased cardiovascular mortality
and with vascular calcifications in dialysis patients [7]. An
human ELISA for the measurement of the fully bioactive
form (phosphorylated, carboxylated MGP) is still not
available on the market. The positive association described
in the present study between dp-ucMGP and BMI or CRP
has also been described by others [25,26]. The negative as-
sociation discovered here with plasma albumin and the
positive one with FGF-23 levels, and with dialysis vintage,
on the other hand, has not been found to date in HD pa-
tients, and this deserves further investigations.
There are several limitations to our study. First, our
population was a prevalent HD population and the study
is observational. Further studies with incident cases and
follow-up of hard endpoints would be welcome. More-
over, our HD population was relatively older (71 ± 17 years
old), in comparison with other studies (67 ± 13 y in Schur-
gers’s study [25] and 59 ± 11 y in Schlieper [7]). Because
age is a well-known determinant of vascular calcifications,
different results might be observed in younger HD pa-
tients. Second, it would be interesting to confirm whether
patients being treated with VKA have a higher risk of vas-
cular calcifications. This was not the case in our popula-
tion (data not shown) but our sample of prevalent VKA
treated patients (n = 23) was probably too small. Severalauthors have suggested that VKA treatment is a risk factor
for vascular calcifications or calciphylaxis in HD patients
but this assertion deserves further study [24,32,35,39-46].
Third, the Kauppila method is not the most sensitive way
of detecting vascular calcifications and we did not directly
measure neither vitamin K levels nor other vitamin K
dependent protein like PIVKA-II (protein induced by vita-
min K absence II). However, the Kauppila method is the
approach recommended by the KDIGO [30]. Lastly, we
do not have precise data regarding the VKA adequacy
(INR are not available) and the duration of VKA therapy
in all patients. However, VKA is widely prescribed for
atrial fibrillation or valve replacement and therefore, long
term therapy must be considered in the majority of our
treated patients.
Conclusions
In this observational study, we confirmed high levels of dp-
ucMGP in HD patients. For the first time, we used an auto-
mated and efficient assay to measure dp-ucMGP. We con-
firmed the potential usefulness of MGP (dp-ucMGP or
another active isoform) in the assessment of vascular calci-
fications, although this finding has, to date, been the subject
of debate in the literature. For the first time, we showed
that dp-ucMGP levels were much higher in HD patients
being treated with VKA. This observation underlines the
specific role of the inactive form of MGP, dp-ucMGP (mea-
sured by the automated assay) in assessing vitamin K status.
This measurement could be of great interest in monitoring
the vitamin K therapy if future randomized studies, notably
the VitaVasK trial [34], confirm the effectiveness of this vita-
min in HD patients [18,28,32,34,35,39,44,47,48].
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